Advanced Search

 

Study ID Status Title Patient Level Data
S3AB3006 Completed A multicentre, double-blind, randomised, parallel group study to compare the efficacy and safety of two ondansetron regimens in the control of emesis and nausea induced by cancer chemotherapy in paediatric patients.
S3AB3008 Completed A multicentre, double-blind, double-dummy, parallel group study to compare the efficacy and safety of intravenous ondansetron 8mg plus intravenous dexamethasone 20mg with oral ondansetron 24mg od plus oral dexamethasone 12mg od in the control of acute emesis and nausea induced by cisplatin chemo ...
S3AC01 Completed A randomised, double-blind, placebo controlled, multicentre, parallel group study to evaluate the efficacy and safety of a single intravenous bolus dose of ondansetron in the prevention of postoperative nausea and emesis in patients having general anaesthesia and undergoing elective orthopaedic ...
S3AM23 Completed A Multicentre Double-blind Study to Compare the Efficacy and Safety of Ondansetron (GR 38032F) Administered Either as a Single Intravenous Dose or a Continuous Infusion in the Prophylaxis of Acute Nausea and Vomiting Induced by Cisplatin-containing Cancer Chemotherapy Regimens
S3AP31 Completed To Compare the Efficacy and Safety of Ondansetron with Dexamethasone in the Prophylaxis of Nausea and Vomiting Induced by Non-Platinum-Containing Cancer Chemotherapy Regimens
S3AP36 Completed A Multi-Centre Study to Assess the Clinical Efficacy and Safety of GR38032F in the Prophylaxis of Cisplatin-Induced Nausea and Vomiting
S3AP47 Completed A Pilot Study to Determine the Optimal Dose, Tolerance and Efficacy of Ondansetron (GR38032F) in the Prevention of Nausea and Vomiting Induced by Maintenance Therapy Used in Children with Acute Lymphoblastic Leukaemia
S3AP48 Completed A Pilot Study to Determine the Safety and Efficacy of Ondansetron (GR38032F) in the Prevention of Nausea and Vomiting Induced by Cancer Chemotherapy Regimens Containing Cisplatin, Carboplatin or Doxorubicin in Combination with either Cyclophosphamide or Ifosfamide in Children
S3AP54 Completed The pharmacokinetics of oral ondansetron (GR38032F) in elderly patients receiving cytotoxic chemotherapy or radiotherapy.
S3AT03 Completed A Randomised Double-Blind Multicentre Study to Compare the Clinical Efficacy and Safety of Ondansetron (GR38032F) and Metoclopramide in the Prophylaxis of Single Fraction Radiotherapy-Induced Nausea and Vomiting
S3AT07 Completed A Randomised, Double-Blind, Placebo Controlled Study Of The Efficacy And Safely Of Ondansetron (GR38032F) in The Prophylaxis Of Nausea And Vomiting Induced By The Combination Of Cyclophosphamide, Doxorubicin And Prednisolone With Vincristine (CHOP), VP16 Or VM26
S3AT17 Completed A Randomised Double-Blind Placebo-Controlled Study of the Efficacy and Safety of Ondansetron Given Orally 8mg Three Times A Day in the Prophylaxis of Nausea and Vomiting Induced by the Combination of Cyclophosphamide, Methotrexate and 5-Fluorouracil (CMF) in Women with Breast Cancer
S3AT20 Completed Comparison of Ondansetron vs Ondansetron + Dexamethasone in the control of delayed emesis and nausea induced by Cisplatin.
S3AV01 Completed A randomised, double-blind, placebo controlled, multicentre, parallel group study to evaluate the efficacy and safety of a single intravenous bolus dose of ondansetron in the prevention of postoperative nausea and emesis in patients having general anaesthesia and undergoing elective abdominal su ...
S3AV02 Completed A randomised, double-blind, placebo controlled, multicentre, parallel group study to evaluate the efficacy and safety of a single intravenous bolus dose of ondansetron in the prevention of postoperative nausea and emesis in patients having general anaesthesia and undergoing major gynaecological ...
S3B10903 Completed An Open-Label, Non-Randomized, Single-Dose Study of the Pharmacokinetics of Alosetron 1mg in Children 6-11 Years of Age With Non-Constipated Irritable Bowel Syndrome
S3B10909 Completed Alosetron (GR68755): Phase I study (evaluation of the effect of food in healthy volunteer).
S3B10910 Completed To assess the effects of GR68755C on psychological and psychomotor responses to amphetamine in healthy volunteers.
S3B10916 Completed A study to evaluate the effects of GR68755 on memory and information processing when co-administered with scopolamine in young healthy volunteers
S3B10917 Completed Initial safety and tolerability study with intravenous GR68755 in human volunteers.
S3B10919 Completed Initial safety and tolerability study with oral doses of GR68755 in human volunteers.
S3B10924 Completed A study to investigate the duration of effect of oral GR68755 on intradermal 5-HT induced flare response in volunteers
S3B10932 Completed A double-blind, randomized-step study of the effect of alosetron 1 mg, 2 mg, and 4 mg BID versus placebo on QT and QTc following 4 days of administration in healthy females.
S3B10934 Completed An Open-Label, Non-Randomized, Single-Dose Study of the Pharmacokinetics of Alosetron 1mg in Adolescents 12-17 Years of Age With Non-Constipated Irritable Bowel Syndrome
S3B10935 Completed An open-label, non-randomized, two-way cross-over trial to evaluate the effect of multiple-dose alosetron administration (1 mg PO BID for 14 days) on the pharmacokinetics of single-dose fluoxetine (PROZAC) administration in healthy subjects.

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.